Citicoline (Recognan) solution 100 mg/ml 10 ml – [10 vials]

Citicoline, being a precursor of the key ultrastructural components of the cell membrane (mainly phospholipids), has a broad spectrum of action: it helps restore the damaged cell membranes, inhibits the action of phospholipases, preventing the excessive formation of free radicals, and also prevents cell death by acting on apoptosis mechanisms.

In the acute period of stroke it reduces the volume of brain tissue damage, improves cholinergic transmission.

In craniocerebral trauma it reduces the duration of post-traumatic coma and severity of neurological symptoms, besides, it helps to reduce the duration of recovery period.

Citicoline is effective in treating cognitive, sensory and motor neurological disorders of degenerative and vascular etiology.

In chronic cerebral ischemia citicoline is effective in the treatment of disorders such as memory impairment, lack of initiative, difficulties in performing daily activities and self-care.

It increases the level of attention and consciousness, as well as reduces the manifestation of amnesia.

– The acute phase of ischemic stroke (in the complex therapy).

– The recovery period of ischemic and hemorrhagic strokes.

– Craniocerebral trauma (CTS), acute (as part of complex therapy) and recovery period.

– Cognitive and behavioral disorders in degenerative and vascular diseases of the brain.

Contraindications .

Do not prescribe for patients with marked vagotonia (predominance of the tone of the parasympathetic part of the autonomic nervous system) and with hypersensitivity to any of the components of the drug.

Rare hereditary diseases associated with fructose intolerance.

Due to lack of sufficient clinical data, it is not recommended for use in children under 18 years of age.

Caution:

There is no information on relative contraindications to the use of the drug.

Pregnancy and lactation:

Sufficient data on the use of citicoline in pregnant women are not available. Although no adverse effects have been observed in animal studies, during pregnancy, the drug Recognan® is prescribed only when the expected benefits to the mother outweigh the potential risk to the fetus.

When prescribing Recognan® during lactation, women should stop breastfeeding because there is no data on excretion of citicoline with the woman’s milk.

 

• Recognan®, solution for oral administration, is administered orally. Before use, the drug may be diluted in a small amount of water (120 ml or 1/2 cup).
• It is taken during or between meals.
• Recommended dosage regimen
• Acute period of ischemic stroke and traumatic brain injury (TBI):
• 1000 mg (10 ml or 1 sachet) every 12 hours. Duration of treatment at least 6 weeks.
• Recovery period of ischemic and hemorrhagic strokes, recovery period of CHT, cognitive and behavioral disorders in degenerative and vascular diseases of the brain:
• 500-2000 mg daily (5-10 ml 1-2 times daily or 1 sachet (1000 mg) 1-2 times daily). Dosage and duration of treatment depending on the severity of the symptoms.
• Elderly patients.
• No dosage adjustment is required for elderly patients when prescribing Recognan®.
• Instructions for use of the dispensing pipette supplied with the bottle:

 

• After each use, it is recommended to rinse the pipette dispensing water.
• Recommendations for use of the drug Recognan® in sachets: